MDMA (3,4-Methylenedioxymethamphetamine)

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• US DEA: MDMA (3,4-Methylenedioxymethamphetamine) — Schedule I Classification, FDA Breakthrough Therapy Designation for PTSD (2017), Phase 3 Trial Results, and Adulterant Contamination Concerns (2023) REGULATORY · 2023
• NIDA Research Report: MDMA (Ecstasy/Molly) — Serotonergic Neurotoxicity, Hyperthermia, Hyponatremia (SIADH), Adolescent Vulnerability, CYP2D6 Pharmacogenomics, and Harm Reduction Strategies (2023) ACADEMIC · 2023
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• where to look Hazardous Substances Data Bank (HSDB), as recorded by PubChem (Experimental Properties, CID 1615; where-to-look, not a source of this value) DATABASE · 2026
• EPA CompTox CTX API: predicted properties for DTXSID90860791 (MDMA (3,4-Methylenedioxymethamphetamine)) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.